We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Lynparza Label Now Includes Breast Cancer
Read MoreHide Full Article
AstraZeneca, plc (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the FDA has approved the supplemental New Drug Application (sNDA) for Lynparza seeking approval for label expansion in metastatic breast cancer. Lynparza is presently marketed for advanced ovarian cancer.
With the latest FDA approval, Lynparza can now be used to treat previously treated (chemotherapy) patients with HER2-negative metastatic breast cancer, harboring germline BRCA mutations. Moreover, the drug is also approved in patients with HR+ breast cancer who were treated with an endocrine therapy or were ineligible for the same.
The approval makes Lynparza the first approved PARP-inhibitor for treating metastatic breast cancer. Also, first time a PARP inhibitor has been approved beyond ovarian cancer
AstraZeneca’s shares have increased 24.8% in the last year, while shares of Merck are down 5.9% in that period. Meanwhile, the industry moved up 19.1% in the same time period.
The FDA approved the label expansion based on data from the phase III OlympiAD study, which evaluated Lynparza against a chemotherapy. The drug achieved significant improvement in progression-free survival (“PFS”) compared to chemotherapy (7.0 vs 4.2 months). Lynparza also reduced the risk of disease progression or death by 42% and achieved an objective response rate (“ORR”) of 52%, double compared to chemotherapy’s 23%.
Patients will be selected based on Myriad Genetics, Inc.’s (MYGN - Free Report) FDA-approved companion diagnostic test.
Although there is no cure for metastatic breast cancer, Lynparza will offer a new treatment option which lengthens the duration of disease progression. Per the press release, there are 155,000 patients in the United States with metastatic breast cancer who have an inherited BRCA mutation.
Lynparza registered sales of $197 million in the first nine months of 2017, growing 26% year over year. This label expansion will certainly boost the prospect of the drug and give it an advantage over other drugs in the PARP inhibitor segment, which includes Clovis Oncology, Inc.’s Rubraca and Tesaro’s Zejula. Rubraca and Zejula are approved only for ovarian cancer. Both the drugs are also being developed in breast cancer.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
AstraZeneca's Lynparza Label Now Includes Breast Cancer
AstraZeneca, plc (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the FDA has approved the supplemental New Drug Application (sNDA) for Lynparza seeking approval for label expansion in metastatic breast cancer. Lynparza is presently marketed for advanced ovarian cancer.
With the latest FDA approval, Lynparza can now be used to treat previously treated (chemotherapy) patients with HER2-negative metastatic breast cancer, harboring germline BRCA mutations. Moreover, the drug is also approved in patients with HR+ breast cancer who were treated with an endocrine therapy or were ineligible for the same.
The approval makes Lynparza the first approved PARP-inhibitor for treating metastatic breast cancer. Also, first time a PARP inhibitor has been approved beyond ovarian cancer
AstraZeneca’s shares have increased 24.8% in the last year, while shares of Merck are down 5.9% in that period. Meanwhile, the industry moved up 19.1% in the same time period.
The FDA approved the label expansion based on data from the phase III OlympiAD study, which evaluated Lynparza against a chemotherapy. The drug achieved significant improvement in progression-free survival (“PFS”) compared to chemotherapy (7.0 vs 4.2 months). Lynparza also reduced the risk of disease progression or death by 42% and achieved an objective response rate (“ORR”) of 52%, double compared to chemotherapy’s 23%.
Patients will be selected based on Myriad Genetics, Inc.’s (MYGN - Free Report) FDA-approved companion diagnostic test.
Although there is no cure for metastatic breast cancer, Lynparza will offer a new treatment option which lengthens the duration of disease progression. Per the press release, there are 155,000 patients in the United States with metastatic breast cancer who have an inherited BRCA mutation.
Lynparza registered sales of $197 million in the first nine months of 2017, growing 26% year over year. This label expansion will certainly boost the prospect of the drug and give it an advantage over other drugs in the PARP inhibitor segment, which includes Clovis Oncology, Inc.’s Rubraca and Tesaro’s Zejula. Rubraca and Zejula are approved only for ovarian cancer. Both the drugs are also being developed in breast cancer.
Zacks Rank
AstraZeneca carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>